Home > Healthcare > Medical Devices > Diagnostic Devices > Pancreatic Cancer Diagnostic Market

Pancreatic Cancer Diagnostic Market Size

Report ID: GMI9826
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Pancreatic Cancer Diagnostic Market Size

Pancreatic Cancer Diagnostic Market size was valued at around USD 6 billion in 2023 and is estimated to grow at 9.1% CAGR from 2024 to 2032. Pancreatic cancer diagnostics involve various methods and technologies used to detect and evaluate pancreatic cancer. This encompasses a range of procedures, tests, and tools aimed at identifying the presence of cancerous cells in the pancreas, determining the stage and extent of the disease, and guiding treatment decisions.

Pancreatic Cancer Diagnostic Market

To get key market trends

Download Free Sample

The incidence of pancreatic cancer is on the rise globally, becoming a significant health concern. This increase is attributed to factors such as aging populations, lifestyle changes, and environmental influences. Pancreatic cancer remains one of the most lethal forms of cancer due to its typically late diagnosis and rapid progression. The growing number of cases underscores the urgent need for improved diagnostic methods that can detect the disease at an earlier, more treatable stage.

Pancreatic Cancer Diagnostic Market Report Attributes
Report Attribute	Details
Base Year:	2023
Pancreatic Cancer Diagnostic Market Size in 2023:	USD 6 Billion
Forecast Period:	2024 - 2032
Forecast Period 2024 - 2032 CAGR:	9.1%
2032 Value Projection:	USD 12.9 Billion
Historical Data for:	2021 – 2023
No. of Pages:	298
Tables, Charts & Figures:	470
Segments covered:	Product, Test Type, Cancer Type, End-use, and Region
Growth Drivers:	Increasing prevalence of pancreatic cancer Advancements in diagnostic technologies Growing healthcare expenditure globally Rising awareness regarding early cancer detection
Pitfalls & Challenges:	Stringent regulatory scenarios High cost of diagnostic tests

Learn more about the key segments shaping this market

Download Free Sample

For instance, in 2024, the American Cancer Society estimates that approximately 66,440 individuals in the U.S. will be diagnosed with pancreatic cancer, with 34,530 men and 31,910 women affected. Additionally, the disease is expected to cause around 51,750 deaths, including 27,270 men and 24,480 women. Thus, this escalating prevalence is a critical driver for the pancreatic cancer diagnostic market, pushing for the development and adoption of more effective screening and diagnostic tools.

Furthermore, advancements in diagnostic technologies are transforming pancreatic cancer detection. Innovations such as enhanced imaging, next-generation sequencing which is estimated to reach USD 47 billion by 2032, liquid biopsies, and advanced biomarker assays enable earlier and more accurate detection. These technologies improve diagnostic precision and facilitate personalized treatment by providing detailed molecular and genetic insights. This continuous technological evolution stimulates the market, offering hope for earlier intervention and improved patient outcomes.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Pancreatic cancer diagnostic industry size was worth USD 6 billion in 2023 and will expand at an 9.1% CAGR between 2024 and 2032 owing to rising incidence of pancreatic cancer worldwide and ongoing R&D efforts to improve diagnostic methods.

The imaging test segment in the pancreatic cancer diagnostic industry registered USD 2.2 billion in 2023, propelled by the critical role imaging plays in early and accurate detection of pancreatic cancer coupled with non-invasive nature and increasing accessibility of these imaging modalities.

North America pancreatic cancer diagnostic industry will record USD 4.7 billion by 2032 due to the region's advanced healthcare infrastructure, widespread adoption of advanced diagnostic technologies and government initiatives promoting cancer awareness.

Key players operating in the pancreatic cancer diagnostic industry are Abbott Laboratories, Agilent Technologies, Inc., ASURAGEN, INC., Becton, Dickinson and Company, Canon Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies Inc., Hitachi, Ltd., Illumina, Inc., Myriad Genetics, Inc., and Prestige Biopharma Limited (PBP), among others.